Relmada Therapeutics, Inc.

Relmada Therapeutics is dedicated to developing innovative and novel treatments for improving human health. Our team intends to focus on the research and development of transformative medicines for those living with debilitating disorders.

Relmada Therapeutics is advancing a strategic and innovative pipeline of potential high-value assets grounded in strong scientific rationale and positive proof-of-concept data. Our lead programs, NDV-01 and sepranolone, supported by compelling early clinical results, are positioned to reach key clinical milestones in 2026. NDV-01 has demonstrated a 90% overall response rate in Phase 2a for non-muscle invasive bladder cancer (NMIBC), with a Phase 3 trial planned for the first half of 2026. Sepranolone, backed by promising data in Tourette syndrome, is progressing toward a Phase 2b trial in Prader-Willi syndrome.

With a seasoned leadership team, robust product exclusivity, and a strong financial foundation, Relmada is well-positioned to execute efficiently and create long-term value. Our focus is clear: advancing transformative therapies through disciplined, capital-efficient development to ultimately improve the lives of people living with challenging conditions.